Vical Incorporated ( VICL ) Q3 2013 Earnings Conference Call October 31, 2013 12:00 PM ..... Presentation Operator Good day and welcome ladies and gentlemen to the Vical Incorporated financial results conference call. At this time, I would like
MSCI , MYL , NI , NIHD , NILE , NMM , NVO , NYT , O , OCN , OSK , PDCE , PNW , PPL , PRGO , PRLB , PWR , Q , RFP , SCG , SFY , SHOO , SMP , SNAK , SNE , STRA , TDC , TE , TEVA , TWC , VICL , VPHM , VRX , WNR , WWE , XOM Post your comment!
By C.R. Jackson : Cambridge, Massachusetts-based bluebird bio ( BLUE ) is a $710M market cap clinical-stage biotechnology company that is developing gene therapies for severe genetic and orphan diseases. Founded in 1992, the company was formerly known as Genetix Pharmaceuticals, Inc . The company's
By IPOdesktop : Based in Ames, Iowa, NewLink Genetics ( NLNK ) scheduled a $61 million IPO with a market capitalization of $198 million at a price range mid-point of $11 for Thursday, November 10, 2011. The full IPO calendar for the week of November 7 includes five scheduled IPOs. SUMMARY Focused
We are no longer providing equity research on Vical VICL . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
Vical VICL has reported positive preclinical results from its H1N1 swine flu vaccine, but we will maintain our fair value estimate until
Vical VICL announced strong first-quarter results and a collaboration with the U.S. Navy on swine flu, or H1N1 influenza, Thursday
We are maintaining our fair value estimate for Vical VICL as its development progress remains on track. The firm burned through $7 million in cash during the fourth quarter and ended
On Friday, Vical VICL announced plans to restructure its operations. While this will reduce its near-term cash burn, we are holding firm to our fair
After running more valuation scenarios, we're returning our fair value uncertainty rating for Vical VICL to very high from extreme. Our fair value estimate remains unchanged. Our current valuation depends on Vical obtaining about